RxDoctor Payments Data

Christina Crawford

Psychiatric/Mental Health · Omaha, NENPI 1598217119

Payments from drug & device makers

$859in general payments, 2019–2025

Across 29 payments — averaging $29.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$269
  • Supernus Pharmaceuticals, Inc.$125
  • Vanda Pharmaceuticals Inc.$94
  • Otsuka America Pharmaceutical, Inc.$56
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • Sunovion Pharmaceuticals Inc.$41
  • plus $227 from 9 others

What the payments were for

  • Food & beverage$81395%
  • Education$475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$859 in reported general payments places this provider in the 45th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$31,156
Medicare patients
65
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl169$219,427
Invega SustennaPaliperidone Palmitate34$124,276
RexultiBrexpiprazole38$56,003
AristadaAripiprazole Lauroxil17$49,224
TrintellixVortioxetine Hydrobromide55$31,071
GeodonZiprasidone Hcl12$16,304
Clozapine160$12,414
Seroquel XrQuetiapine Fumarate20$9,856
Chlorpromazine Hcl25$7,889
Lurasidone Hcl33$7,415
Methylphenidate ErMethylphenidate Hcl23$7,409
Aripiprazole125$6,968
Ziprasidone Hcl61$6,906
Atomoxetine Hcl32$5,919
Desvenlafaxine Succinate ErDesvenlafaxine Succinate140$4,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$33$124,27634 claims
Otsuka America Pharmaceutical, Inc.Rexulti$56$56,00338 claims
Alkermes, Inc.Aristada$40$49,22417 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$31,07155 claims
Lilly USA, LLCOlanzapine$27$2,212144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →